Structure Therapeutics
Hui Lei is a seasoned professional in the field of chemistry, currently serving as Senior Vice President of Chemistry at Structure Therapeutics since August 2019, after holding the position of Vice President of Chemistry. Prior experience includes leading chemistry departments at Jing Medicine Technology and Eli Lilly China, where Hui Lei focused on drug discovery in oncology, immunology, and neuroscience. With a strong background in medicinal chemistry, Hui Lei has directed teams, overseen multiple technology platforms, and established collaborative models to translate academic research into viable drug discovery projects. Educational qualifications include a B.S. in Chemistry from Peking University and a Ph.D. in Chemistry from the University of Illinois Chicago.
This person is not in any offices
Structure Therapeutics
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.